Loading
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Previous close
$5.00
+$0.05 · +1.01%
After-hours
$5.00
$0.00 · 0.00%
Oct 9, 5:09 PM ET
Regular session · ET · Market data may be delayed.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Day range
Current $5.00
52-week range
Current $5.00
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
71
Bullish
Risk
65
High Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Day range
Current $5.00
52-week range
Current $5.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 62.9M USD | 7.87M USD | — | — | — |
| Cost of goods sold | 8.44M USD | 7.08M USD | — | — | — |
| Gross profit | 54.46M USD | 795K USD | — | — | — |
| Research and development | 115.11M USD | 524.19M USD | 71.29M USD | 87.82M USD | 69.04M USD |
| Selling, general, and administrative | 151.56M USD | 69.23M USD | 28.53M USD | 31.92M USD | 24.28M USD |
| Operating expenses | 267.52M USD | 593.42M USD | 99.82M USD | 119.73M USD | 93.32M USD |
| Interest income | 21.43M USD | 27.06M USD | 24.61M USD | 7.45M USD | 2.96M USD |
| Interest expense | 13.68M USD | 341K USD | — | — | — |
| Depreciation and amortization | 1.74M USD | 683K USD | 222K USD | 199K USD | 184K USD |
| Operating income | −213.06M USD | −592.63M USD | −99.82M USD | −119.73M USD | −93.32M USD |
| Net income | −204.63M USD | −567.94M USD | −75.8M USD | −104.2M USD | −86.85M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.50
310.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI58.96M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM32.83M0.04%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF18.87M0.02%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO11.52M0.08%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO9.65M0.05%18B USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB9.64M0.09%10.28B USD0.44%$206.49+3.00%
State Street SPDR S&P Pharmaceuticals ETFXPH6.99M1.54%461.57M USD0.35%$64.65+1.60%
Schwab U.S. Small-Cap ETFSCHA6.93M0.03%21.73B USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
